In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
This report provides an updated overview on the progress of national COVID-19 vaccination strategies and deployment in European Union/European Economic Area (EU/EEA) countries, including updates on overall vaccine uptake and uptake by target group and vaccination strategies and policies.
This document reports on one of ECDC’s multi-country studies in the hospital setting to measure product-specific COVID-19 VE against any laboratory-confirmed SARS-CoV-2 infection among healthcare workers (HCWs) eligible for vaccination.
Influenza is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. The best way to prevent flu is by getting a flu vaccine each year.
The purpose of this document is to address the safety of donors and products involving Substances of Human Origin (SoHO) and the potential risk of thrombosis with thrombocytopenia adverse events following COVID-19 vaccination of a donor.
ECDC, together with the European Commission’s Directorate-General for Health and Food Safety, and supported by the Commission’s Directorate-General for Neighbourhood and Enlargement Negotiations, organised a stress test of the logistical aspects of COVID-19 vaccination deployment plans for the Western Balkans.